Evaluating Islet Cell Isolation and Transplantation From Donors Following Medical Assistance in Dying.

Journal

Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 08 03 2024
revised: 08 05 2024
accepted: 10 04 2024
medline: 24 6 2024
pubmed: 24 6 2024
entrez: 24 6 2024
Statut: epublish

Résumé

Limited information is available regarding outcomes of islet cell isolation (ICI) and transplantation (ITx) using medical assistance in dying (MAiD) donors. We aimed to assess the feasibility and outcomes of ICI and ITx in MAiD donors. ICI and ITx from MAiD were compared with donation after circulatory death (DCD) type III between 2016 and 2023. Differences of isolated islet equivalents (IEQs), numeric viability and other quantitative in vitro metabolic measures were assessed. Overall, 81 ICIs were available of whom 34 (42%) and 47 (58%) from MAiD and DCD-III, respectively. There were no differences of pancreas and digested tissue weight and islets viability among the 2 groups; however, cold ischemic time was longer in MAiD (11.5 versus 9.1 h; ICI from MAiD donor pancreas may be successfully transplanted with comparable outcomes to DCD-III and may be used for research. These results justify additional efforts to consider MAiD as another valuable source of grafts for ITx. Further multicenter studies and larger clinical experience are needed to validate our findings.

Sections du résumé

Background UNASSIGNED
Limited information is available regarding outcomes of islet cell isolation (ICI) and transplantation (ITx) using medical assistance in dying (MAiD) donors. We aimed to assess the feasibility and outcomes of ICI and ITx in MAiD donors.
Methods UNASSIGNED
ICI and ITx from MAiD were compared with donation after circulatory death (DCD) type III between 2016 and 2023. Differences of isolated islet equivalents (IEQs), numeric viability and other quantitative in vitro metabolic measures were assessed.
Results UNASSIGNED
Overall, 81 ICIs were available of whom 34 (42%) and 47 (58%) from MAiD and DCD-III, respectively. There were no differences of pancreas and digested tissue weight and islets viability among the 2 groups; however, cold ischemic time was longer in MAiD (11.5 versus 9.1 h;
Conclusions UNASSIGNED
ICI from MAiD donor pancreas may be successfully transplanted with comparable outcomes to DCD-III and may be used for research. These results justify additional efforts to consider MAiD as another valuable source of grafts for ITx. Further multicenter studies and larger clinical experience are needed to validate our findings.

Identifiants

DOI: 10.1097/TXD.0000000000001667 PMID: 38911274 PMC: PMC11191926
pubmed: 38911274
doi: 10.1097/TXD.0000000000001667
pii: TXD-2024-0074
pmc: PMC11191926
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e1667

Informations de copyright

Copyright © 2024 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.

Déclaration de conflit d'intérêts

The authors declare no funding or conflicts of interest.

Auteurs

Alessandro Parente (A)

Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.
ORCID: 0000-0001-5506-224X

Kevin Verhoeff (K)

Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.

Tatsuya Kin (T)

Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.

Joshua Hefler (J)

Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.

Braulio A Marfil-Garza (BA)

Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Tecnologico de Monterrey, The Institute for Obesity Research, Monterrey, CP, Mexico.

Norberto Sanchez-Fernandez (N)

Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.

Anna Lam (A)

Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.

James Lyon (J)

Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.

Doug O'Gorman (D)

Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.

Khaled Z Dajani (KZ)

Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.

Blaire L Anderson (BL)

Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.

David L Bigam (DL)

Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.

Patrick E MacDonald (PE)

Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Department of Pharmacology, University of Alberta, Edmonton, AB, Canada.

A M James Shapiro (AMJ)

Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.

Classifications MeSH